FDA Weighs Approval of Moderna's mRNA Flu Vaccine mFlusiva Amid Political Scrutiny
Key Insights
Moderna's mFlusiva (search), the first mRNA-based flu vaccine, showed stronger protection than traditional flu shots in a trial of over 40,000 adults aged 50 and older.
Independent FDA advisers voted unanimously in June to recommend approval, with experts calling it a "critical step forward" in influenza (search) vaccine technology.
mRNA technology enables faster reformulation and production compared to traditional vaccines, offering advantages against emerging flu strains and potential pandemics.
The Food and Drug Administration is expected to decide as soon as today whether to approve mFlusiva (search), the first influenza (search) vaccine developed using mRNA technology. The vaccine, created by Moderna—the same company behind one of the two mRNA COVID-19 vaccines—would mark a significant expansion of the mRNA platform beyond the pandemic setting.
The decision arrives amid heightened political sensitivity around mRNA technology, with Health Secretary Robert F. Kennedy Jr. and other top Trump administration officials having expressed hostility toward mRNA vaccines. The FDA initially refused to even review mFlusiva (search), only reconsidering after intense blowback, according to NPR health correspondent Rob Stein.
Clinical Evidence and Efficacy
Moderna tested mFlusiva (search) in a trial involving more than 40,000 participants. The data demonstrated that the vaccine is safe and appears to produce stronger protection than traditional influenza (search) vaccines in people aged 50 and older. Based on these findings, independent FDA advisers voted unanimously in June to recommend that the agency approve the vaccine.
Michael Osterholm, an infectious disease expert at the University of Minnesota, described the development in stark terms: "I think this is really a critical step forward in advancing influenza (search) vaccine technology, and I think it's just imperative that the FDA come down with an affirmative decision."
Advantages of the mRNA Platform
Beyond the potential for stronger protection, mRNA-based influenza (search) vaccines offer practical advantages over conventional approaches. The technology allows vaccines to be updated much more easily—if a new strain suddenly emerges, as occurred during the past flu season, the vaccines can be reformulated more quickly to maintain or improve their protective match. This capability would be especially critical if a novel flu strain evolved to spark another influenza pandemic.
MRNA vaccines can also be produced much faster than traditional vaccines. Osterholm emphasized this point: "Right there, that is a game-changer in a major way."
Opposition and Controversy
Despite the unanimous advisory committee recommendation, mFlusiva (search) faces opposition rooted in lingering anger over COVID-19 vaccine mandates and misinformation about mRNA safety. Dr. Brian Hooker, chief scientific officer at Children's Health Defense—an antivaccine group once headed by Kennedy—voiced concerns about the technology's novelty.
"I really believe that this technology is just too new. There has not been the adequate level of study of the implications for, you know, literally everybody," Hooker said. "I just feel like the train is leaving the station, and we're not ready yet."
The Trump administration has also slashed hundreds of millions of dollars for research into new mRNA vaccines and made it harder to obtain COVID-19 shots, adding further uncertainty to the regulatory trajectory of mRNA-based products.
What Comes Next
All eyes are now on the FDA as it weighs whether to follow the recommendation of its independent advisers. The decision will not only determine the availability of a new influenza (search) vaccine option for older adults but also signal the regulatory posture toward mRNA technology under the current administration.